Ann: Trading Halt, page-57

This Capital raising is definitely an interesting event. The way I see it, I can see this going 1 of 4 ways:

1) Capital raise focused on bringing in a cornerstone investor. At the same time, could buy out the stake of the big sellers (good)
2) New significantly larger clinical trials now being planned and underway, requiring significantly more capital (good)
3) Funding shortfall for planned activities and requiring more cash just to see results (bad)
4) Raising the level of cash in the RAC Balance sheet to be more appealing as a potential takeover target

Either way, the context of this raise is significantly more important than the raise itself. Companies raise moeny all the time, especially when they're pre-revenue. Option 3 above whilst bad, it's not the end of the world if your belief in the 3 Pillar strategy potential pay-off is the same, it simply changes the denominator in your rate of return calculation.

I noticed Dr. T was fairly quite over the weekend, so I think he was pretty busy pulling this together.

GLTAH DYOR